HOME > TOP STORIES
TOP STORIES
-
BUSINESS Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
February 3, 2016
-
BUSINESS Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
February 2, 2016
-
BUSINESS Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
-
BUSINESS Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
-
REGULATORY Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
January 28, 2016
-
TRENDS 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
TRENDS Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
REGULATORY Gilead’s 2 Hep C Drugs Likely to Face Some 30% Price Cut under “Huge Seller” Re-Pricing: Jiho Estimate
January 25, 2016
-
ORGANIZATION JPMA Expels Kaketsuken over GMP Violations, Cover-Up
January 22, 2016
-
BUSINESS Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
-
REGULATORY “Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
January 20, 2016
-
REGULATORY Discussions on Market Price Survey for 2017 Revision Likely to Begin in March, Conclusion Expected in June
January 19, 2016
-
REGULATORY New ICH Trial Guidelines to Embrace “Pooled Populations,” but PMDA Unlikely to Accept Zero Japanese
January 18, 2016
-
REGULATORY Research-Driven Makers Should Find Another Biz Model If They Can’t Innovate: Top Bureaucrat
January 15, 2016
-
BUSINESS Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
-
ORGANIZATION JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
January 13, 2016
-
REGULATORY Re-Pricing Rule for “Huge-Seller” Drugs Necessary Compromise to Protect Universal Healthcare While Promoting Innovation: Health Minister
January 12, 2016
-
REGULATORY Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
-
ORGANIZATION EFPIA Japan Chief Raps Huge Seller Re-Pricing, Says April Reform Will Chill the Market
January 8, 2016
-
ORGANIZATION April Drug Price Revision “Will Be a Hard One” for the Industry: Pharma Leader Nakayama
January 7, 2016
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…